{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:42:11Z","timestamp":1792640531030,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Emerging data suggest dalbavancin may be used in complicated infections, including bacteremia, prosthetic joint infections, osteomyelitis, and endovascular infections. This study aimed to evaluate the real-world safety and effectiveness of dalbavancin for the treatment of invasive gram-positive infections (GPIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, retrospective cohort study included adult patients who received dalbavancin for treatment of confirmed or presumed invasive GPIs. Patients were excluded if they received dalbavancin for chronic suppression. The intention-to-treat (ITT) population comprised patients who received at least 1 dalbavancin dose. The per-protocol (PP) population received at least 2 doses. The primary outcome was clinical failure in the PP group at 90 days post treatment. Secondary outcomes were the proportion of logistical failures, clinical failures, and treatment-emergent adverse events in the ITT group at 90 days post treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 194 patients included in the PP population, 29.4% (57\/194) experienced clinical failure at 90 days post treatment. Active intravenous drug use and lack of reliable transportation were factors significantly associated with higher odds of clinical failure in a multivariable regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dalbavancin is a safe and effective treatment option for invasive GPIs; however, risk factors are associated with higher odds of clinical failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf301","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:22:48Z","timestamp":1761830568000},"page":"389-397","source":"Crossref","is-referenced-by-count":5,"title":["Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections"],"prefix":"10.1093","volume":"83","author":[{"given":"Jake","family":"Crocker","sequence":"first","affiliation":[{"name":"Prisma Health Upstate , Greenville, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Yunusa","sequence":"additional","affiliation":[{"name":"University of South Carolina College of Pharmacy , Columbia, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Brandon","family":"Bookstaver","sequence":"additional","affiliation":[{"name":"University of South Carolina College of Pharmacy , Columbia, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Derrick","sequence":"additional","affiliation":[{"name":"Prisma Health Richland , Columbia, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Ann","family":"Justo","sequence":"additional","affiliation":[{"name":"Dartmouth Hitchcock Medical Center , Lebanon, NH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M","family":"Jones","sequence":"additional","affiliation":[{"name":"St. Joseph\u2019s\/Candler Health System , Savannah, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P","family":"White","sequence":"additional","affiliation":[{"name":"University of Oklahoma Medical Center at OU Health , Oklahoma City, OK ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8730-8929","authenticated-orcid":false,"given":"Joseph","family":"Sassine","sequence":"additional","affiliation":[{"name":"University of Oklahoma Medical Center at OU Health , Oklahoma City, OK ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Belk","sequence":"additional","affiliation":[{"name":"Huntsville Hospital , Huntsville, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Pizzuti","sequence":"additional","affiliation":[{"name":"Prisma Health Richland , Columbia, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026040814545213700_zxaf301-B1","author":"Dalbavancin"},{"key":"2026040814545213700_zxaf301-B2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2020.11.018","article-title":"Efficacy and safety of dalbavancin in the treatment of gram-positive bacterial infections","volume":"24","author":"Wang","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"8","key":"2026040814545213700_zxaf301-B3","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1093\/jac\/dkac178","article-title":"Dalbavancin in gram-positive periprosthetic joint infections","volume":"77","author":"Simon","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2026040814545213700_zxaf301-B4","doi-asserted-by":"publisher","first-page":"ofab589","DOI":"10.1093\/ofid\/ofab589","article-title":"Effectiveness of dalbavancin compared with standard of care for the treatment of osteomyelitis: a real-world analysis","volume":"9","author":"Cain","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"2026040814545213700_zxaf301-B5","first-page":"532","article-title":"Dalbavancin for treating prosthetic joint infections caused by gram-positive bacteria: a proposal for a low dose strategy. A retrospective cohort study","volume":"32","author":"Buz\u00f3n Mart\u00edn","year":"2019","journal-title":"Rev Esp Quimioter"},{"issue":"7","key":"2026040814545213700_zxaf301-B6","doi-asserted-by":"publisher","first-page":"ofac335","DOI":"10.1093\/ofid\/ofac335","article-title":"Comparison of sequential dalbavancin with standard-of-care treatment for Staphylococcus aureus bloodstream infections","volume":"9","author":"Molina","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2026040814545213700_zxaf301-B7","doi-asserted-by":"publisher","first-page":"106842","DOI":"10.1016\/j.ijantimicag.2023.106842","article-title":"Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy","volume":"62","author":"Frazier","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026040814545213700_zxaf301-B8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"10","key":"2026040814545213700_zxaf301-B9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"2026040814545213700_zxaf301-B10","doi-asserted-by":"publisher","first-page":"e02260","DOI":"10.1128\/AAC.02260-20","article-title":"Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections","volume":"65","author":"Cojutti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026040814545213700_zxaf301-B11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of dalbavancin","volume":"61","author":"Molina","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2026040814545213700_zxaf301-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmacy10010001","article-title":"Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care","volume":"10","author":"Antosz","year":"2021","journal-title":"Pharmacy (Basel)"},{"issue":"4","key":"2026040814545213700_zxaf301-B13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40121-020-00347-w","article-title":"Financial analysis of dalbavancin for acute bacterial skin and skin structure infections for self-pay patients","volume":"9","author":"Pizzuti","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"1","key":"2026040814545213700_zxaf301-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"2026040814545213700_zxaf301-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026040814545213700_zxaf301-B16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1017\/ice.2015.317","article-title":"Peripherally inserted central venous catheter complications in children receiving outpatient parenteral antibiotic therapy (OPAT)","volume":"37","author":"Kovacich","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"2026040814545213700_zxaf301-B17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1017\/ice.2018.107","article-title":"A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy","volume":"39","author":"Schrank","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"2026040814545213700_zxaf301-B18","doi-asserted-by":"publisher","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2026040814545213700_zxaf301-B19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40121-024-00933-2","article-title":"Dalbavancin sequential therapy for gram-positive bloodstream infection: a multicenter observational study","volume":"13","author":"Rebold","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026040814545213700_zxaf301-B20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae186","article-title":"Real-world dalbavancin use for serious gram-positive infections: comparing outcomes between people who use and do not use drugs","author":"Zambrano","journal-title":"Open Forum Infect Dis"},{"issue":"Published online August 13, 2025","key":"2026040814545213700_zxaf301-B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial","author":"Turner","journal-title":"JAMA."},{"issue":"7","key":"2026040814545213700_zxaf301-B22","doi-asserted-by":"publisher","first-page":"e1443","DOI":"10.1093\/cid\/ciaa1730","article-title":"Stewarding the costly antibiotic: considerations for dalbavancin","volume":"73","author":"Bookstaver","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2026040814545213700_zxaf301-B23","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/jac\/dkad331","article-title":"Dalbavancin plasma concentrations in 133 patients: a PK\/PD observational study","volume":"78","author":"Hervochon","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026040814545213700_zxaf301-B24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae315","article-title":"Simulated target attainment of multidose regimens of dalbavancin for prolonged durations of therapy","author":"Volk","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2026040814545213700_zxaf301-B25","doi-asserted-by":"publisher","first-page":"106960","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2026040814545213700_zxaf301-B26","doi-asserted-by":"publisher","first-page":"107038","DOI":"10.1016\/j.ijantimicag.2023.107038","article-title":"Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections","volume":"63","author":"Cojutti","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"2026040814545213700_zxaf301-B27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s15010-020-01435-2","article-title":"Outcome of spinal implant-associated infections treated with or without biofilm-active antibiotics: results from a 10-year cohort study","volume":"48","author":"K\u00f6der","year":"2020","journal-title":"Infection"},{"issue":"19","key":"2026040814545213700_zxaf301-B28","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"issue":"1","key":"2026040814545213700_zxaf301-B29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf301\/65050650\/zxaf301.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/8\/389\/65050650\/zxaf301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/8\/389\/65050650\/zxaf301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:54:57Z","timestamp":1775674497000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/8\/389\/8307565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf301","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,10,31]]}}}